Anika EVP’s RSUs Vest; Shares Withheld for Taxes

Anika Therapeutics EVP and General Counsel David Colleran reported equity award vesting and related tax withholding, not open-market trading.

Rhea-AI Filing Summary

Anika Therapeutics EVP and General Counsel David Colleran reported equity award vesting and related tax withholding, not open-market trading. On March 14, 2026 and March 15, 2026, he exercised a total of 15,837 restricted stock units into the same number of common shares at $0.00 per share.

He also received a grant or award of 4,694 common shares. To cover tax obligations on these RSU and PSU vestings, 4,168 and 1,893 shares of common stock were withheld at $14.20 per share. Following these transactions, Colleran directly holds 67,570 shares of Anika Therapeutics common stock, with additional RSU awards continuing to vest over time as indicated in the footnotes.

Insider Trade Summary

15,837 shares exercised/converted

Exercise 7 txns

Insider Colleran David

Role EVP, General Counsel, Corp Sec

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,449	$0.00	$0.00
Exercise	Common Stock	6,449	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,893	$14.20	$27K
Exercise	Restricted Stock Unit	9,388	$0.00	$0.00
Exercise	Common Stock	9,388	$0.00	$0.00
Grant/Award	Common Stock	4,694	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,168	$14.20	$59K

Holdings After Transaction: Restricted Stock Unit — 25,225 contracts (Direct); Common Stock — 67,570 shares (Direct)

Footnotes (6)

1. F1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
2. F2. On March 14, 2025, the Reporting Person was granted 14,082 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.
3. F3. Reflects an aggregate of 4,694 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.
4. F4. Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.
5. F5. On March 14, 2025, the Reporting Person was granted 28,165 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.
6. F6. On March 15, 2024, the Reporting Person was granted 19,345 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Anika Therapeutics (ANIK) report for David Colleran?

David Colleran reported equity award vesting and tax withholding transactions. He exercised restricted stock units into common stock and received an additional share award, while shares were withheld by the issuer to satisfy tax obligations tied to these vestings.

How many shares did David Colleran acquire in Anika Therapeutics (ANIK) through RSU exercises?

David Colleran exercised 15,837 restricted stock units into common shares. This includes 9,388 RSUs converted on March 14, 2026, and 6,449 RSUs converted on March 15, 2026, each RSU representing one share of Anika Therapeutics common stock.

Were any of David Colleran’s Anika Therapeutics (ANIK) shares sold on the open market?

The reported dispositions were tax-withholding events, not open-market sales. A total of 4,168 and 1,893 common shares were retained by the issuer at $14.20 per share to cover tax liabilities from RSU and PSU vesting.

What is David Colleran’s direct Anika Therapeutics (ANIK) shareholding after these Form 4 transactions?

After the reported transactions, David Colleran directly holds 67,570 common shares. This figure reflects his position following RSU conversions, the additional share grant, and the share amounts withheld by the issuer for tax obligations.

What equity awards for David Colleran at Anika Therapeutics (ANIK) were vesting in March 2026?

The footnotes reference both RSU and PSU awards granted in prior years. They describe performance-based phantom RSUs granted March 14, 2025 and time-based RSUs granted March 14, 2025 and March 15, 2024, with the March 2026 transactions reflecting initial and second vesting installments.

Does David Colleran’s Form 4 for Anika Therapeutics (ANIK) indicate routine compensation activity?

The transactions appear to be routine equity compensation events. They involve RSU and PSU vesting, related share issuances, and issuer share withholding for taxes, with no open-market purchases or sales reported in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Colleran David

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel, Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		M		9,388	A	(1)	62,488	D
Common Stock	03/14/2026		A		4,694(2)	A	$0	67,182	D
Common Stock	03/14/2026		F		4,168(3)	D	$14.2	63,014	D
Common Stock	03/15/2026		M		6,449	A	(1)	69,463	D
Common Stock	03/15/2026		F		1,893(4)	D	$14.2	67,570	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/14/2026		M			9,388	(5)	(5)	Common Stock	9,388	$0	18,777	D
Restricted Stock Unit	(1)	03/15/2026		M			6,449	(6)	(6)	Common Stock	6,449	$0	6,448	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

2. On March 14, 2025, the Reporting Person was granted 14,082 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.

3. Reflects an aggregate of 4,694 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.

4. Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.

5. On March 14, 2025, the Reporting Person was granted 28,165 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.

6. On March 15, 2024, the Reporting Person was granted 19,345 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.

	/s/ David Colleran	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.